ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 33,481 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $57.23 on Friday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -104.05 and a beta of 0.71. The company’s fifty day moving average is $58.26 and its 200-day moving average is $60.74. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the business posted $1.05 earnings per share. The business’s quarterly revenue was up 12.5% on a year-over-year basis. Equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Innealta Capital LLC bought a new stake in ANI Pharmaceuticals during the second quarter worth approximately $65,000. Ridgewood Investments LLC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at $106,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after acquiring an additional 579 shares during the period. Finally, XTX Topco Ltd acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth $207,000. 76.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on ANIP shares. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Raymond James increased their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Finally, Truist Financial boosted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.